Edgewise Therapeutics/EWTX

$16.43

0.37%
-
1D1W1MYTD1YMAX

About Edgewise Therapeutics

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. It has built its muscle-focused drug discovery platform. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. Its lead product candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. Its product candidate, EDG-7500, for the treatment of hypertrophic cardiomyopathy addition to exploring the potential of its mechanism in the treatment of disorders of diastolic dysfunction.

Ticker

EWTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Kevin Koch

Employees

88

Headquarters

Boulder, United States

EWTX Metrics

BasicAdvanced
$1.52B
Market cap
-
P/E ratio
-$1.57
EPS
-
Beta
-
Dividend rate
$1.52B
$20.69
$5.12
935.22K
19.498
-28.33%
-30.1%
-29.73%
3.617
4.781
-24.25%

What the Analysts think about EWTX

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
85.64% upside
High $48.00
Low $24.00
$16.43
Current price
$30.50
Average price target

EWTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-30.1M
17.12%
Profit margin
0%
-

EWTX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 8.29%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.36
-$0.34
-$0.41
-$0.47
-
Expected
-$0.36
-$0.40
-$0.40
-$0.43
-$0.39
Surprise
0%
-14.57%
3.54%
8.29%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Edgewise Therapeutics stock?

Edgewise Therapeutics (EWTX) has a market cap of $1.52B as of April 15, 2024.

What is the P/E ratio for Edgewise Therapeutics stock?

The price to earnings (P/E) ratio for Edgewise Therapeutics (EWTX) stock is 0 as of April 15, 2024.

Does Edgewise Therapeutics stock pay dividends?

No, Edgewise Therapeutics (EWTX) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Edgewise Therapeutics dividend payment date?

Edgewise Therapeutics (EWTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Edgewise Therapeutics?

Edgewise Therapeutics (EWTX) does not currently have a Beta indicator.

What is the Edgewise Therapeutics stock price target?

The target price for Edgewise Therapeutics (EWTX) stock is $30.5, which is 85.64% above the current price of $16.43. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Edgewise Therapeutics stock

Buy or sell Edgewise Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing